Clinical Trial Update: A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating two doses of ritlecitinib for alopecia areata in people aged 12 years and older, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 3 | Status: RECRUITING